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Oligodeoxynucleotides (ODN) which contain immunostimulatory CG motifs (CpG ODN) can promote T
helper 1 (Th1) responses, an adjuvant activity that is desirable for vaccination against leishmaniasis. To test
this, susceptible BALB/c mice were vaccinated with soluble leishmanial antigen (SLA) with or without CpG
ODN as adjuvant and then challenged with Leishmania major metacyclic promastigotes. CpG ODN alone gave
partial protection when injected up to 5 weeks prior to infection, and longer if the ODN was bound to alum.
To demonstrate an antigen-specific adjuvant effect, a minimum of 6 weeks between vaccination and infection
was required. Subcutaneous administration of SLA alone, SLA plus alum, or SLA plus non-CpG ODN resulted
in exacerbated disease compared to unvaccinated mice. Mice receiving SLA plus CpG ODN showed a highly
significant (P < 5 3 1025) reduction in swelling compared to SLA-vaccinated mice and enhanced survival
compared to unvaccinated mice. The modulation of the response to SLA by CpG ODN was maintained even
when mice were infected 6 months after vaccination. CpG ODN was not an effective adjuvant for antibody
production in response to SLA unless given together with alum, when it promoted production of immunoglob-
ulin G2a, a Th1-associated isotype. Our results suggest that with an appropriate antigen, CpG ODN would
provide a stable, cost-effective adjuvant for use in vaccination against leishmaniasis.
Since the discovery of bacterial DNA as a sequence-specific
immunostimulatory agent (31, 52), interest has been generated
in the use of oligodeoxynucleotides (ODN) as vaccine adju-
vants. Specific DNA sequences involving an unmethylated CG
dinucleotide (CpG motif) have been shown to directly activate
B-cell proliferation and immunoglobulin (Ig) synthesis (22)
and to promote macrophage/dendritic cell cytokine and major
histocompatibility complex class II expression (5, 44, 46). DNA
can induce the synthesis of cytokines such as interleukin-12
(IL-12), tumor necrosis factor alpha (TNF-a), and IL-6 from
macrophages (5, 29, 45, 46) and in mixed spleen cell culture
results in efficient induction of alpha/beta and gamma inter-
ferons (IFN-a/b and -g) (5, 14, 52). The early IFN-g produced
in these cultures and in vivo in response to administered im-
munostimulatory DNA derives from natural killer cells stimu-
lated by macrophage production of IL-12 and TNF-a (5, 14).
IL-12 and IFN-g are involved in development of T helper 1
(Th1)-polarized immune responses, and in earlier studies
DNA has proved a promising adjuvant for promotion of Th1
responses (7, 11, 28, 37, 47, 50). The search for effective and
safe Th1-promoting adjuvants is an active field, as most estab-
lished vaccines use alum adjuvant, which results in a bias to
Th2 responses characterized by IgG1 and IgE production and
lack of specific cytotoxic T lymphocytes (11). This is not desir-
able for the clearance of many parasitic and viral diseases
which require cell-mediated rather than just humoral re-
sponses.
Stabilized CpG ODN (ODN containing immunostimulatory
CG motifs) has been used as an adjuvant with a range of
antigens (7, 11, 28, 37, 47, 50). It was found that CpG adjuvants
induced higher levels of IgG2a (a Th1-promoted isotype) than
complete Freund’s adjuvant (7, 47, 50) and were as effective as
complete Freund’s adjuvant in tumor antigen immunization
(50). Specific cytotoxic T-lymphocyte production has also been
shown when CpG ODN with alum or liposomes (11, 28) was
used for adjuvant. The efficacy of DNA adjuvants has not yet
been assessed in an infectious disease model.
Mouse models of infection with the protozoan parasite
Leishmania major have helped define the Th1/Th2 model, as
Th1-polarized responses are curative and Th2 responses exac-
erbate or are ineffective in controlling the disease (reviewed in
references 23, 27, and 36). L. major replicates intracellularly in
macrophages, and effective control requires macrophage acti-
vation and nitric oxide (NO)-mediated killing in response to
the Th1-produced cytokine IFN-g. BALB/c mice are suscepti-
ble to infection with L. major, and if allowed to run its course,
subcutaneous injection of parasites leads to uncontrolled le-
sion growth and eventual death. Resistant mice such as
CBA/Ca mice resolve lesions and heal within a few weeks. The
specific defect in BALB/c mice has not been identified, but this
difference in response of the mouse strains is due to a balance
between effects of the Th1-promoting cytokine IL-12 and Th2
cytokine IL-4. BALB/c mice show an early peak of IL-4 pro-
duction in draining lymph nodes by 1 day after infection, an
effect not seen in resistant mice (24). This early IL-4 seems to
determine the course of the infection, resulting in subsequent
development of leishmania-specific CD41 T cells along the
Th2 pathway. Interestingly, the early IL-4 is uniquely produced
by CD41 cells expressing T-cell receptor chains Vb4 and Va8,
which recognize the leishmanial LACK antigen (24), and prior
tolerization of BALB/c mice to LACK make them resistant to
L. major infection (18). Anti-IL-4 treatment or administration
of IL-12 with infection can give BALB/c mice the ability to
control the disease. The apparently straightforward role of
IL-4 in promoting disease has been complicated by recent
conflicting reports on disease progression in IL-4 knockout
mice (21, 34). Other work has suggested that BALB/c CD41
cells rapidly lose responsiveness to IL-12 during antigen-in-
duced differentiation and thus have an inherent bias to the Th2
lineage (12).
Treatments and vaccinations which control the disease in
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susceptible mice invariably promote Th1 responses over Th2
responses. In human disease, there is also a trend of Th1
responses being involved in subclinical or curing disease and
Th2 responses being involved in progressive disseminated dis-
ease (reviewed in reference 19). Vaccination strategies should
clearly aim to produce Th1-promoting cytokines such as IL-12
at the time of cellular response to antigen. There is no gener-
ally used vaccine against leishmaniasis, although a number of
human trials using killed leishmanial promastigotes with My-
cobacterium bovis BCG are under way, and initial results show
some protection (3). Vaccine approaches which have yielded
various degrees of protection in mouse models of infection
include DNA vaccination (13, 43, 49, 51), subcutaneous (s.c.)
injection of low numbers of virulent L. major (4), use of Sal-
monella (30) or BCG (8) vectors expressing leishmanial anti-
gen, antigen-containing liposomes (38), and ISCOMs (immu-
nostimulatory complexes) (35), and use of IL-12 (2, 33) or
Corynebacterium parvum (15, 40) as adjuvant. Conversion of
the strong BALB/c Th2 response to a protective response is a
stringent challenge for a vaccine, and most of these protocols
gave only partial protection to BALB/c mice. Some of the most
promising published results with methods potentially transfer-
rable to human use are with DNA vaccination (13) and IL-12
adjuvant (2, 33). Early vaccinations with irradiated promastig-
otes showed protection (perhaps due to tolerization rather
than vaccination [1]) with intraperitoneal and intravenous in-
jections but exacerbation if administered s.c. (17, 26). Of these
routes, intraperitoneal and intravenous are clearly not practi-
cal for human vaccination, but it now seems that with appro-
priate use of adjuvants, s.c. vaccination becomes possible (2).
In this study, we have investigated the use of s.c.-injected
immunostimulatory DNA as an adjuvant with crude leishma-
nial antigen in protection against L. major infection.
MATERIALS AND METHODS
Mice and materials. Female BALB/c mice were obtained from Tuck Ltd.
(Battlesbridge, England) or Charles River Ltd. (Margate, England), and female
CBA/Ca were obtained from Harlan Olac Ltd. (Bicester, England). Phosphoro-
thioate-linked ODN were obtained from either Genosys Biotechnologies (Pamp-
isford, England) or Oligos Etc. (Wilsonville, Oreg.). CpG ODN used were AAC
(ACC GAT AAC GTT GCC GGT GAC G) (46) and AO-1 (GCT CAT GAC
GTT CCT GAT GCT G). The non-CpG ODN used was AAG (ACC GAT AAG
CTT GCC GGT GAC G). DNA from Micrococcus lysodeikticus was from Sigma
(Poole, England) and purified by phenol-chloroform extraction. IL-12 was from
either Peprotech EC Ltd. (London, England) or R&D Systems (Abingdon,
England).
Preparation of SLA. Soluble leishmanial antigen (SLA) was prepared from
log-phase L. major LV39 (MRHO/SU/59/P) by sonication and ultracentrifuga-
tion as described previously (40) except that a2-macroglobulin was omitted from
the preparation.
Vaccinations. Vaccines were prepared in phosphate-buffered saline and con-
tained combinations of the following: 20 mg of SLA, 50 mg of oligonucleotide or
bacterial DNA, 0.5 mg of IL-12, and 250 mg of aluminum hydroxide adjuvant
(alum). Aluminum hydroxide gel was prepared by the method of Chace (6). SLA
and DNA were bound directly to the alum by incubation for 30 min at room
temperature. Micrococcal DNA was sheared by sonication and boiled to prevent
clumping of the alum. The level of binding assessed by A260 and protein assays
of supernatant was complete for protein and 95 to 99% for DNA. Seven- to
eight-week-old mice were vaccinated twice at a 2-week interval s.c. in either the
left footpad or the rump.
Infection of animals. L. major LV39 log-phase promastigotes cryopreserved
from the first passage after transformation from lesion-derived amastigotes were
seeded at 106 cells/ml in high-glucose Dulbecco modified Eagle medium with
10% fetal calf serum and cultured for 11 to 14 days. Promastigotes harvested at
this stage were .80% morphologically metacyclic, consistent with our experience
with strain LV39, which transforms to .80% peanut agglutinin binding negative
at 11 to 14 days of culture (9). Parasites (2 3 106) were injected into the right
hind footpad 5 to 6.5 weeks after the second vaccination. Footpad swelling was
measured, and mice were killed according to Home Office requirements when
lesions showed the first signs of ulceration and before the onset of major visceral
disease. Results for different groups were compared by unpaired, two-tailed
Student t tests.
IgG isotype ELISAs. Serum Ig isotypes were assayed by enzyme-linked immu-
nosorbent assay (ELISA) using 0.5 mg of bound SLA per well, isotype-specific
secondary antibodies (biotinylated rabbit anti-mouse IgG2a or IgG1; Zymed
Laboratories Inc., San Francisco, Calif.), and streptavidin-biotinylated horserad-
ish peroxidase (Amersham, Little Chalfont, England). The most frequently used
approach for comparing Ig levels is an endpoint dilution, the titer being deter-
mined by the last dilution at which activity is detectable. However, accuracy is
compromised by serial dilutions and the inherent error in the low absorbance
values toward the endpoint. Use of a standard serum has been suggested as a
preferred alternative (42). Here, results from individual mouse samples were
compared with a pooled standard serum prepared from infected mice vaccinated
with alum-SLA-AAC. Using a standard curve of dilutions of this pooled serum
in each experiment, we assessed the relative level of Ig in a dilution of individual
samples. The results obtained are therefore expressed as Ig isotype level relative
to the pooled standard. To enable the best comparison, appropriate dilutions of
each sample giving values on the steepest part of the standard curve were used.
This technique for comparing Ig levels depends on the assumption that the shape
of the dilution curve is similar for each sample, and from titrations of various
samples this seemed a reasonable assumption. The standard had high detectable
levels of IgG2a and IgG1, both with a titer of 105, so that graphs give an
indication of levels of the two isotypes relative to one another, assuming that
detection is equally efficient with the two isotype-specific antibodies.
Nitrite assay. A nitrite assay was used as an indication of NO production by
RAW264, a murine macrophage line, as described previously (48).
RESULTS
Immunostimulatory ODN modulate L. major infection. To
check the efficacy of phosphorothioate-stabilized CpG ODN as
an adjuvant with L. major SLA as antigen, footpad swelling in
mice vaccinated with SLA plus CpG ODN was compared with
that in unvaccinated controls (Fig. 1). A significant difference
was observed at 3 (P , 0.01) and 4 (P , 0.005) weeks postin-
fection. Improved survival was also observed, with all of five
vaccinated mice surviving until week 11 and three of five re-
maining healthy at week 17, whereas five of six unvaccinated
mice had to be killed between weeks 4 and 6. However, injec-
tion of CpG ODN alone also gave some protection (P , 0.05)
from footpad swelling at 3 and 4 weeks compared with control
unvaccinated mice, although footpads continued to swell and
three of five mice had to be killed in week 6. Since there was
no antigen in this preparation this is likely to be due to linger-
ing traces of the ODN directly activating antigen presentation
FIG. 1. Lesion sizes in vaccinated mice challenged with L. major. BALB/c
mice were injected with indicated vaccine preparations in the left footpad, fol-
lowed 2 weeks later by injection s.c. in the rump; 5 weeks later, these mice and
resistant CBA/Ca mice were infected in the right footpad with 2 3 106 L. major
promastigotes, and footpad swelling was monitored weekly. The mean and stan-
dard error of measurements from groups of five or six (control group only) mice
are shown up to the time when the first mouse from that group had to be killed.
Treatments: h, SLA plus CpG ODN (AAC); {, SLA plus non-CpG ODN; E,
CpG ODN; , SLA; n , control unvaccinated mice; }, resistant CBA/Ca mice.
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and macrophages for parasite killing. Previous work has shown
CpG ODN themselves protect from and are therapeutic in L.
major infection (53). In the experiment here, mice were left for
5 weeks between the last vaccination and challenge infection,
indicating that the protective effect of ODN can be long-lived.
SLA alone had an exacerbatory effect on disease progres-
sion. A comparison of SLA-vaccinated and SLA-CpG ODN-
vaccinated mice (Fig. 1) shows the dramatic modifying role of
the ODN on the immune response to antigen (P , 0.00005 at
week 3). The DNA sequence specificity for this immunomodu-
lation is shown by the lack of protection by vaccination with
SLA plus non-CpG ODN, an inactive ODN with the active
sequence AACGTT changed to AAGCTT.
Other potential adjuvants investigated in combination with
SLA were IL-12 and micrococcal DNA. Both of these treat-
ments exacerbated the disease in the same way as SLA alone
(result not shown). The failure of bacterial DNA to behave as
an adjuvant may be due to more rapid breakdown in vivo. The
bacterial DNA is clearly immunologically active, as in an in
vitro assay of NO production by a macrophage cell line, mi-
crococcal DNA was only slightly less potent than CpG ODN
(Fig. 2). In a second assay, the differences at low DNA con-
centration were not so marked (result not shown). SLA–IL-12
is published as a protective vaccination (2) and had been in-
cluded as a positive control. Reasons considered for its failure
to work here include rapid degradation or that 0.5 mg of IL-12
per vaccination was an insufficient dose.
Confirmation of the adjuvant effect of oligonucleotides in
vaccination against L. major. To avoid the problem of macro-
phage activation by traces of CpG ODN remaining at the time
of infection, further experiments were performed, leaving
greater intervals between vaccination and challenge infection.
An interval of 6 weeks between vaccination and infection elim-
inated any protective effect of CpG ODN alone (Fig. 3A and
B). A dramatic effect of oligonucleotide was observed in mod-
ifying the response to SLA vaccination (Fig. 3A). In this ex-
periment, SLA alone had a highly significant exacerbatory ef-
fect on footpad swelling compared to unvaccinated animals
(P , 1026 at week 3) or animals vaccinated with SLA plus
CpG ODN (P , 1027 at week 3). At the time when the first
unvaccinated animals had to be killed at week 5 of infection,
there was no significant difference between the unvaccinated
mice and those which received SLA plus CpG ODN (Fig. 3A).
The response of unvaccinated control mice was variable, with
two of six mice failing to swell above 4-mm footpad depth after
9 weeks of infection. However, analysis of the times at which
mice had to be killed indicates a protective effect for SLA plus
CpG ODN over unvaccinated mice (Fig. 3B). In a repeat
experiment with groups of 10 mice, a similar result was ob-
tained: survival of mice was improved by SLA-CpG ODN
treatment, but again the variability in control mice meant that
no statistical difference in footpad thickness was observed be-
fore the first mice had to be killed.
A lack of adjuvant effect of non-CpG ODN and micrococcal
DNA was confirmed in this experiment (Fig. 3C). As antici-
pated from the known Th2 promotion by alum (11), SLA-alum
was exacerbatory (Fig. 3C). An attempt was made to stabilize
the micrococcal DNA and allow a response by binding it to
alum. Any stabilization afforded by alum binding was not suf-
ficient to give a protective response or could not overcome the
promotion of Th2 responses by alum (Fig. 3C). Despite includ-
ing the protease inhibitor a2-macroglobulin in the SLA for the
SLA–IL-12 sample as detailed in the original published
method (2, 40), again no effect of IL-12 on the response to
SLA was observed.
Previous work had suggested that a combination of alum and
CpG ODN gives both CTL production and high antibody titers
(11). We tried this and found a great effect compared to SLA
alone or SLA plus alum in both footpad swelling and survival
(Fig. 3D and E). Survival was also greater than for unvacci-
nated mice (Fig. 3E). However, the success of this treatment is
not necessarily due to effective vaccination, as mice injected
with alum plus CpG ODN alone showed similar footpad and
survival characteristics (Fig. 3D and E). The alum may have
stabilized the CpG ODN in vivo. Footpad measurements for
the alum-SLA-CpG ODN group were skewed by one mouse
which progressed rapidly and had to be killed in week 5.
The effects of SLA and SLA-CpG ODN vaccinations are
long-lived. To assess the longevity of the immunological mem-
ory response induced by SLA or SLA plus CpG ODN, mice
which had been vaccinated 6 months previously were infected
with L. major and footpad swelling was monitored over 5
weeks. For 6-month vaccinated mice, we observed a modifica-
tion by CpG ODN of the effect of SLA (Fig. 4A) similar to that
observed in animals vaccinated 6 weeks previously (Fig. 4B),
indicating that the memory T-cell response elicited by SLA and
SLA plus CpG ODN is long-lived.
Postvaccination antibody subclass responses to SLA. To
compare IgG isotypes in protective and nonprotective vacci-
nations, sera collected 4 weeks after the second vaccination
were assessed for IgG1 and IgG2a. Figure 5 shows the results
for vaccinated mice from the experiments presented in Fig. 1
and 2. Despite having clearly had a profound effect on the
response to infection, SLA-AAC (CpG ODN) gave little de-
tectable IgG1 or IgG2a (Fig. 5) or indeed total IgG (result not
shown). As expected (11), reasonable levels of IgG1 produc-
tion and no IgG2a were obtained with alum as adjuvant. SLA-
AAG (non-CpG ODN) produced more antibody than SLA-
AAC (CpG ODN) and may have had a slight adjuvant effect
above the effect of SLA alone. Immunostimulatory effects such
as B-cell proliferation and splenomegaly have been observed in
response to non-CpG ODN before (11, 32) and seem to be a
non-sequence-specific response to the phosphorothioate
ODN. The nonprotective treatments SLA-micrococcal DNA
and SLA–IL-12 gave no significant boost in antibodies above
SLA alone. SLA-alum-micrococcal DNA showed a significant
effect of the DNA compared to SLA-alum treatment (P , 0.05
for IgG2a). The ratio between IgG1 and IgG2a is decreased,
FIG. 2. Measurement of nitrite as an indication of NO produced by RAW264
cells in response to DNA. Cells were incubated with IFN-g (40 U/ml) for 1 h
before various concentrations of DNA were added for 24 h. DNAs used: h,
DNA from M. lysodeikticus; {, CpG ODN (AAC); , non-CpG ODN (AAG).
Results are the average of nitrite concentration in triplicate wells.
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suggesting a shift toward a Th1 response (Fig. 5), but this was
clearly insufficient to affect on the outcome of infection (Fig.
3C). The only treatment to give high levels (although highly
variable between mice) of both IgG1 and IgG2a was SLA-
alum-AAC. In summary, there was a surprising lack of adju-
vant effect of CpG ODN alone on antibody production in
response to SLA. The ability of ODN to affect the humoral
immune response was, however, shown in combination with
alum, where it caused a major shift toward IgG2a production.
Immunological correlates of disease protection versus exac-
erbation. Levels of antibody were assessed in infected animals
from the experiment presented in Fig. 3 as a measure of Th1
versus Th2 bias during the course of the disease. Figure 6A
shows up to 1,000-fold differences in IgG1 levels and 100-fold
differences in IgG2a levels between treatment groups. The
absolute level of IgG2a, a Th1 marker, was not related to
disease progression. In particular, SLA-AAG (non-CpG
ODN), which was disease exacerbatory, had a relatively high
IgG2a level, similar to that in the resistant CBA/Ca mice.
However, the ratio of IgG1 to 2a showed some correlation with
disease progression. As shown in Fig. 6B, high ratios (30 to
500) were associated with exacerbation, and moderate ratios (1
to 7) were associated with some protection. The resistant
CBA/Ca mice also fell within this range. Interestingly, all
BALB/c mice which had not been exposed to SLA had lower
overall antibody levels but a higher proportion of IgG2a. These
included mice which showed no difference to control (AAC
and AO-1 treatments) but also the alum-AAC (CpG ODN)
treatment group, which showed enhanced survival. Thus, the
ratio for mice unexposed to SLA was not a good indicator of
disease state. The assumed stability of ODN in the alum-AAC
treatment does not appear to have altered the humoral re-
sponse to infection but may still have been acting directly on
macrophages to enhance killing or bias Th cell development. A
repeat experiment with groups of 10 mice treated with SLA,
CpG ODN, and SLA plus CpG ODN and control mice gave
very similar results and IgG ratios to those presented here.
DISCUSSION
Previous work has demonstrated that immunostimulatory
DNA promotes Th1 responses (7, 11, 37, 53), an adjuvant
FIG. 3. Lesion sizes and survival of vaccinated mice challenged with L. major. BALB/c mice were injected in the left footpad with the indicated vaccine preparations,
followed 2 weeks later by injection s.c. in the rump; 6.3 weeks later, these mice and resistant CBA/Ca were infected in the right footpad with 2 3 106 L. major
promastigotes. All groups contained five mice except for control (six mice) SLA-CpG ODN (10 mice), and CpG ODN-alone (12 mice) groups. Results from groups
of mice treated with either of the CpG ODNs AAC and AO-1 were indistinguishable and were combined to give SLA-CpG ODN and CpG ODN groups in order to
simplify the graphs and improve statistical power. For footpad measurements, results show the mean and standard error up to the time when the first mouse had to
be killed. Mice were killed according to Home Office guidelines when lesions began to ulcerate. (A) Footpad sizes of infected mice in the weeks following infection.
Treatments: h, SLA plus CpG ODN; E, CpG ODN; , SLA; n , control unvaccinated mice; }, resistant CBA/Ca mice. (B) Survival of infected animals. Treatments
were as for panel A. (C) Footpad sizes of mice receiving vaccinations which exacerbated infection. Treatments: , SLA; {, SLA plus non-CpG ODN; }, SLA plus
micrococcal DNA; h, SLA plus alum; F, SLA plus alum and micrococcal DNA; E, SLA plus IL-12; n , control unvaccinated mice. (D) Footpad sizes of mice treated
with SLA plus alum (h) or SLA plus alum and CpG ODN (AAC) () or alum and CpG ODN (AAC) (E). (E) Survival of mice treated as for panel D and of control
unvaccinated mice ( n ).
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activity that would be desirable for vaccination against leish-
maniasis. Results presented here demonstrate that coinjection
of immunostimulatory phosphorothiorate-modified ODN as
adjuvant with a crude soluble leishmanial antigen preparation
modulates leishmania-specific immunity toward a protective
immune response. During the course of these experiments, we
made several important observations which contribute to our
understanding of the requirements for successful immune in-
terventions against leishmaniasis and to the use of BALB/c
mice as a model system.
First, we were able to demonstrate that immunostimulatory
ODN alone could modulate leishmanial infection even when
injected up to 5 weeks prior to challenge infection, and longer
if the ODN was bound to alum. This effect is consistent with
previous studies showing CpG ODN to be a very effective
treatment for cutaneous leishmaniasis when administered at
the time of infection or up to 20 days after infection (53). In
these studies, an established Th2 response in infected mice
could be converted by CpG ODN administration to a Th1-
driven response associated with persistent IL-12 receptor b2-
chain expression. ODN will probably also contribute directly to
parasite killing, as studies demonstrate that DNA activation of
macrophages leads to TNF-a and NO production (45, 46, 48).
Whatever the mechanism, our data support the therapeutic
potential of CpG ODN in the treatment of intramacrophage
pathogens.
To dissociate the nonspecific effect of ODN from leishma-
nia-specific adjuvant activity, we had to wait at least 6 weeks
between the last vaccination and challenge infection. Under
these conditions, we observed a protective effect of vaccination
with SLA and ODN on the length of time before animals
developed ulcerating lesions and had to be killed. The re-
sponse of unvaccinated BALB/c mice to infection in these
experiments was variable, and possible reasons for this are
considered below. This meant that in some experiments it was
not possible to confirm a protective effect of vaccination on
footpad size before the first mice in the control group had to be
killed. However, in no case did vaccination make lesions re-
solve like those of the resistant CBA/Ca mice. Rather, in pro-
tected animals, the footpads remained slightly swollen in a
stable manner for periods of months.
ODN had an unequivocally impressive effect in modulating
the response to vaccination with SLA. Administration of SLA
alone or with alum, bacterial DNA, IL-12, or non-CpG ODN
made the mice uniformly susceptible, with rapid swelling and a
necessity to kill all mice in week 3 of infection. Early studies of
vaccination using irradiated promastigotes found that s.c. in-
jection exacerbated disease compared to controls (26). How-
ever, a more recent study using SLA injected s.c. and intra-
dermally found no exacerbation (2). Exacerbation by SLA in
the absence of any Th1-promoting adjuvant is not surprising in
BALB/c mice, since they have an inherent tendency to develop
Th2 responses. The difference between our results and those of
Afonso et al. (2) may relate to conditions of animal housing
and exposure to environmental antigens as discussed below or
FIG. 4. Lesion sizes in mice challenged with L. major at 6 weeks and 6 months after vaccination. Treatments: , SLA; h, SLA plus CpG ODN (AAC). Results
shown are the mean and standard error of footpad measurements. (A) Groups of three BALB/c mice were vaccinated as for Fig. 3. Six months later, they were infected
in the right footpad with 2 3 106 L. major promastigotes, and footpad size was monitored in the weeks following infection. (B) Groups of 9 (SLA plus CpG ODN)
or 10 (SLA) BALB/c mice were vaccinated twice s.c. in the rump at a 2-week interval; 6.5 weeks later, they were infected in the right footpad at the same time as the
mice used for panel A.
FIG. 5. Relative anti-SLA IgG1 and IgG2a levels in vaccinated mice from
two experiments (i and ii). Mice were bled 4 weeks after the second vaccination.
Antibody levels are expressed relative to a standard pool (see Materials and
Methods). Mean and standard error of Ig levels measured in duplicate on at least
five animals per group are shown. DNAs used are CpG ODNs (AAC and AO-1),
non-CpG ODN (AAG), and micrococcal DNA (mDNA).
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to differences in preparation of SLA and vaccination schedule.
It will be important to establish whether exacerbation can be
avoided with more purified protein fractions, as it is a difficult
task for a vaccine adjuvant to overcome such a powerful neg-
ative effect of antigen alone. Nevertheless, the modulation of
this response to SLA by active ODN in all mice tested shows
the power of these DNA molecules as immunomodulators.
In the experiments performed here, the unvaccinated
BALB/c mice seemed to be teetering on the balance point
between resistance and susceptibility. Twenty to 30% of un-
vaccinated control footpads failed to swell above 4 mm, and
these mice remained healthy until the end of the experiment at
13 weeks. In others, the infection progressed rapidly and mice
with footpads measuring 6 mm had to be killed in week 5. Since
BALB/c resistance can be established with low doses of para-
sites (4), one interpretation is that our parasites were insuffi-
ciently infective. However, this seems unlikely since in many
mice the disease progressed rapidly. It is possible that a vari-
able proportion of nonmetacyclic parasites in our inoculum
contributed to the local inflammatory response initiated at the
site of infection, since it is well established that noninfective
logarithmic-phase parasites elicit a strong macrophage activa-
tion response, whereas metacyclic parasites enter macrophages
silently (10). However this is a factor that is likely to vary
between and not within experiments. Another explanation for
variability in the BALB/c mouse response to infection may lie
in the basis to their susceptibility. As discussed earlier, the
BALB/c response to the leishmanial LACK antigen seems
critical in the early production of IL-4 and subsequent suscep-
tibility (24). The possibility exists that the dominance of the
LACK antigen in BALB/c mice is a consequence of preexpan-
sion of LACK-reactive T cells in response to a cross-reactive
environmental or gut flora antigen. If this is the case, there
could be variable priming with the putative environmental
antigen and thus a variable susceptibility of BALB/c mice to
infection.
Vaccination with SLA plus ODN clearly had a profound
effect on immune response to SLA but did not result in anti-
body production. Production of antibodies is not of concern for
leishmanial vaccine development, as antibody plays little or no
role in defense against leishmania (16). Other studies have also
documented protective antileishmanial vaccination without an-
tibody production (39, 43). The finding of so little induction of
antibody by oligonucleotide adjuvant was surprising, as in most
previous studies using oligonucleotide with antigens such as
hepatitis B surface antigen, fowl gamma globulin, or a tumor
antigen, antibody production with a bias toward the Th1 cyto-
kine-induced subtype, IgG2a, was readily detectable (11, 47,
50). This finding suggests that the lack of antibody production
here may be in some way due to the crude leishmanial extract
used as antigen. Whether SLA contains molecules which spe-
cifically inhibit the humoral response under the cytokine con-
ditions promoted by CpG ODN has not been investigated.
Although in other work SLA with C. parvum adjuvant did
induce a humoral response, sera from vaccinated mice surpris-
ingly precipitated only two leishmanial proteins (40). Fraction-
ation of SLA by ion-exchange chromatography identified only
one protective fraction out of nine, and immunization with this
fraction did not induce antibody production (39). Only vacci-
nations which included alum induced large amounts of anti-
body. Alum with SLA, as expected, gave a large amount of
IgG1 and no IgG2a. Inclusion of active ODN in this prepara-
tion had a profound effect on antibody production, leading to
high levels of both IgG1 and IgG2a. Thus, it seems that alum
and not ODN promoted the general ability to make antibody
in response to SLA, but in the presence of alum, Th1 cytokines
induced by ODN promoted class switching to IgG2a. A com-
bination of alum and CpG ODN as adjuvant may be useful
when both humoral and cell-mediated immunity are desired.
After infection, absolute levels of antibody bore no relation-
ship to the progress of disease, but in mice vaccinated with
SLA and various adjuvants, high ratios of IgG1 to 2a, sugges-
tive of Th2 processes, correlated with exacerbated disease. The
ratio was not predictive for mice which had not received SLA,
as susceptible BALB/c control mice had a lower IgG1/IgG2a
ratio than the resistant CBA/Ca. This contrasts with a report by
Bretscher et al. (4), who determined by immunoblot analysis
that BALB/c mice had readily detectable IgG1 and almost no
IgG2a 1 month after infection with 106 L. major parasites. This
may be yet another manifestation of the incomplete suscepti-
FIG. 6. Relative anti-SLA IgG1 and IgG2a levels in infected mice from the experiment in Fig. 3. Mice were bled 2.5 weeks after infection. Results shown are mean
and standard error of Ig levels measured in duplicate on at least five animals per group. DNAs used were CpG ODNs (AAC and AO-1) and non-CpG ODN (AAG).
(A) Antibody levels expressed relative to a standard pool (see Materials and Methods). (B) Ratio of anti-SLA IgG1 to IgG2a.
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bility of the BALB/c control mice observed in these experi-
ments.
Our experiments failed to show an adjuvant effect of IL-12.
In initial experiments using IL-12 as adjuvant (2), 1 mg of IL-12
was used in vaccinations, but the authors noted similar effects
of vaccinations with SLA plus 1 mg and SLA plus 0.1 mg of
IL-12 on lymph node cell IFN-g induction and IL-4 suppres-
sion. Therefore, we considered that 0.5 mg would be an ade-
quate dose, but this may not have been the case. Although
IL-12 has been a successful adjuvant promoting cell-mediated
immunity to a number of antigens (41), the cost of producing
a recombinant cytokine will probably remain too high for gen-
eral inclusion in adjuvants, particularly for diseases in devel-
oping countries. In addition, storage of vaccines containing
temperature-sensitive components may be challenging in iso-
lated tropical areas. Published results for recombinant IL-12 as
adjuvant should encourage the search for vaccination strate-
gies which enhance the body’s own production of IL-12 and
other Th1-promoting cytokines. Our results contribute to the
promising emerging role for ODN adjuvants and DNA vacci-
nation, both of which depend on macrophage/antigen-present-
ing cell recognition of foreign DNA sequences, induce a range
of Th1-promoting cytokines (20, 25, 29) and are conveniently
stable under field conditions.
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